Harbour BioMed
Mr. Jingsong Wang, M.D., Ph.D., is the Principal Founder, Chairman and Chief Executive Officer. Prior to founding the company, Dr. Wang served as Head of China R&D and Head of Translational Medicine, Asia Pacific, at Sanofi. He is a former attending physician and clinical fellow at Harvard Medical School. Dr. Wang received his Ph.D. in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher ’s laboratory at the Harvard School of Public Health.
Harbour BioMed
1 followers
Harbour BioMed is an Immune-Driven Global Bio-therapeutics Company discovering, developing and delivering Innovative Therapeutics for Oncology and Immunology. The company's discovery and development programs are centered around its two patented transgenic mouse platforms for human antibody discovery - the H2L2 and the HCAb.